Anti-CD3 monoclonal antibody
An anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells. They are immunosuppresive drugs.
The first to be approved was muromonab-CD3 in 1986, to treat transplant rejection.
Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab. They are being investigated for the treatment of other conditions like Crohn's disease, ulcerative colitis and type 1 diabetes,[1] and for inducing immune tolerance.[2][3]
Mechanism of action
[edit]See muromonab-CD3.
See also
[edit]References
[edit]- ^ Herold KC, Taylor L. (2003). "Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?". Immunologic Research. 28 (2): 141–50. doi:10.1385/IR:28:2:141. PMID 14610290. S2CID 7154699.
- ^ Bisikirska; et al. (2005). "TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs". Journal of Clinical Investigation. 115 (10): 2904–2913. doi:10.1172/JCI23961. PMC 1201661. PMID 16167085.
- ^ Bisikirska & Herold; Herold, Kevan C. (2004). "Use of Anti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes". Annals of the New York Academy of Sciences. 1037 (1): 1–9. Bibcode:2004NYASA1037....1B. doi:10.1196/annals.1337.001. PMID 15699486. S2CID 32819214.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |